Karen S Anderson

List of Publications by Year
in descending order

67 papers	5,002 citations	136950 32 h-index	110387 64 g-index
68 all docs	68 docs citations	68 times ranked	8706 citing authors

#	Article	IF	Citations
1	Molecular Definition of Breast Tumor Heterogeneity. Cancer Cell, 2007, 11, 259-273.	16.8	1,273
2	The JAK2/STAT3 signaling pathway is required for growth of CD44+CD24â€“ stem cellâ€“like breast cancer cells in human tumors. Journal of Clinical Investigation, 2011, 121, 2723-2735.	8.2	777
3	The Sentinel Within:Â Exploiting the Immune System for Cancer Biomarkersâ€. Journal of Proteome Research, 2005, 4, 1123-1133.	3.7	297
4	TCR contact residue hydrophobicity is a hallmark of immunogenic CD8⁺T cell epitopes. Proceedings of the National Academy of Sciences of the United States of America, 2015, 112, E1754-62.	7.1	200
5	Protein Microarray Signature of Autoantibody Biomarkers for the Early Detection of Breast Cancer. Journal of Proteome Research, 2011, 10, 85-96.	3.7	197
6	Application of Protein Microarrays for Multiplexed Detection of Antibodies to Tumor Antigens in Breast Cancer. Journal of Proteome Research, 2008, 7, 1490-1499.	3.7	140
7	Oral Human Papillomavirus (HPV) Infection in HPV-Positive Patients With Oropharyngeal Cancer and Their Partners. Journal of Clinical Oncology, 2014, 32, 2408-2415.	1.6	139
8	Multifunctional CRISPR-Cas9 with engineered immunosilenced human T cell epitopes. Nature Communications, 2019, 10, 1842.	12.8	126
9	Genomic amplification of 9p24.1 targeting JAK2, PD-L1, and PD-L2 is enriched in high-risk triple negative breast cancer. Oncotarget, 2015, 6, 26483-26493.	1.8	118
10	p53 Autoantibodies as Potential Detection and Prognostic Biomarkers in Serous Ovarian Cancer. Cancer Epidemiology Biomarkers and Prevention, 2010, 19, 859-868.	2.5	95
11	Autoantibody Signature for the Serologic Detection of Ovarian Cancer. Journal of Proteome Research, 2015, 14, 578-586.	3.7	90
12	The shared tumor-associated antigen cytochrome P450 1B1 is recognized by specific cytotoxic T cells. Blood, 2003, 102, 3287-3294.	1.4	77
13	A Conserved E7-derived Cytotoxic T Lymphocyte Epitope Expressed on Human Papillomavirus 16-transformed HLA-A2+ Epithelial Cancers. Journal of Biological Chemistry, 2010, 285, 29608-29622.	3.4	71
14	The neoepitope landscape of breast cancer: implications for immunotherapy. BMC Cancer, 2019, 19, 200.	2.6	68
15	Phase I/II Combined Chemoimmunotherapy with Carcinoembryonic Antigenâ€“Derived HLA-A2â€“Restricted CAP-1 Peptide and Irinotecan, 5-Fluorouracil, and Leucovorin in Patients with Primary Metastatic Colorectal Cancer. Clinical Cancer Research, 2005, 11, 5993-6001.	7.0	62
16	Human Papilloma Virus Specific Immunogenicity and Dysfunction of CD8+ T Cells in Head and Neck Cancer. Cancer Research, 2018, 78, 6159-6170.	0.9	61
17	Immunotherapy for the Treatment of Breast Cancer. Current Oncology Reports, 2015, 17, 5.	4.0	59
18	HPV Serum Antibodies as Predictors of Survival and Disease Progression in Patients with HPV-Positive Squamous Cell Carcinoma of the Oropharynx. Clinical Cancer Research, 2015, 21, 2861-2869.	7.0	59

#	Article	IF	Citations
19	Public health impact of delaying second dose of BNT162b2 or mRNA-1273 covid-19 vaccine: simulation agent based modeling study. BMJ, The, 2021, 373, n1087.	6.0	59
20	Rapid detection of antibodies in sera using multiplexed self-assembling bead arrays. Journal of Immunological Methods, 2009, 350, 171-182.	1.4	58
21	Autoantibody biomarkers for the detection of serous ovarian cancer. Gynecologic Oncology, 2017, 146, 129-136.	1.4	53
22	Biomarkers and Strategies for Early Detection of Ovarian Cancer. Cancer Epidemiology Biomarkers and Prevention, 2020, 29, 2504-2512.	2.5	53
23	HPV16 antibodies as risk factors for oropharyngeal cancer and their association with tumor HPV and smoking status. Oral Oncology, 2015, 51, 662-667.	1.5	51
24	Biomarker Discovery for Heterogeneous Diseases. Cancer Epidemiology Biomarkers and Prevention, 2013, 22, 747-755.	2.5	49
25	Modelling the effect of early detection of Ebola. Lancet Infectious Diseases, The, 2015, 15, 148-149.	9.1	46
26	JAK2 and PD-L1 Amplification Enhance the Dynamic Expression of PD-L1 in Triple-negative Breast Cancer. Clinical Breast Cancer, 2018, 18, e1205-e1215.	2.4	46
27	Plasma Autoantibodies Associated with Basal-like Breast Cancers. Cancer Epidemiology Biomarkers and Prevention, 2015, 24, 1332-1340.	2.5	42
28	Tracking humoral responses using self assembling protein microarrays. Proteomics - Clinical Applications, 2008, 2, 1518-1527.	1.6	39
29	Modeling the Subclonal Evolution of Cancer Cell Populations. Cancer Research, 2018, 78, 830-839.	0.9	37
30	Tumor Vaccines for Breast Cancer. Cancer Investigation, 2009, 27, 361-368.	1.3	36
31	A versatile protein microarray platform enabling antibody profiling against denatured proteins. Proteomics - Clinical Applications, 2013, 7, 378-383.	1.6	34
32	Biologic predictors of serologic responses to HPV in oropharyngeal cancer: The HOTSPOT study. Oral Oncology, 2015, 51, 751-758.	1.5	34
33	Autoantibodies in cancer: prognostic biomarkers and immune activation. Expert Review of Proteomics, 2011, 8, 577-589.	3.0	32
34	Application of flat panel OLED display technology for the point-of-care detection of circulating cancer biomarkers. Scientific Reports, 2016, 6, 29057.	3.3	29
35	Proteomic mapping of p53 immunogenicity in pancreatic, ovarian, and breast cancers. Proteomics - Clinical Applications, 2016, 10, 720-731.	1.6	26
36	Isolation, Detection, and Quantification of Cancer Biomarkers in HPV-Associated Malignancies. Scientific Reports, 2017, 7, 3322.	3.3	26

#	Article	IF	Citations
37	Artificial antigen-presenting cells expressing CD80, CD70, and 4-1BB ligand efficiently expand functional T cells specific to tumor-associated antigens. Immunobiology, 2014, 219, 583-592.	1.9	25
38	Salivary and serum HPV antibody levels before and after definitive treatment in patients with oropharyngeal squamous cell carcinoma. Cancer Biomarkers, 2017, 19, 129-136.	1.7	22
39	Development and validation of a novel clinical fluorescence in situ hybridization assay to detect JAK2 and PD-L1 amplification: a fluorescence in situ hybridization assay for JAK2 and PD-L1 amplification. Modern Pathology, 2017, 30, 1516-1526.	5.5	22
40	Stage Dependence, Cell-Origin Independence, and Prognostic Capacity of Serum Glycan Fucosylation, Î²1â€“4 Branching, Î²1â€“6 Branching, and Î±2â€“6 Sialylation in Cancer. Journal of Proteome Research, 2018, 17, 543-558.	3.7	19
41	Tumorâ€associated autoantibodies as early detection markers for ovarian cancer? A prospective evaluation. International Journal of Cancer, 2018, 143, 515-526.	5.1	18
42	Overlapping synthetic peptides encoding TPD52 as breast cancer vaccine in mice: Prolonged survival. Vaccine, 2009, 27, 1825-1833.	3.8	17
43	Serum Immune Profiling for Early Detection of Cervical Disease. Theranostics, 2017, 7, 3814-3823.	10.0	17
44	Diagnostic accuracy of serum antibodies to human papillomavirus type 16 early antigens in the detection of human papillomavirusâ€related oropharyngeal cancer. Cancer, 2017, 123, 4886-4894.	4.1	16
45	A Noninvasive Blood-based Combinatorial Proteomic Biomarker Assay to Detect Breast Cancer in Women over age 50 with BI-RADS 3, 4, or 5 Assessment. Clinical Cancer Research, 2019, 25, 142-149.	7.0	16
46	Autoantibodies in Early Detection of Breast Cancer. Cancer Epidemiology Biomarkers and Prevention, 2020, 29, 2475-2485.	2.5	16
47	Programmable protein arrays for immunoprofiling HPVâ€associated cancers. Proteomics, 2016, 16, 1215-1224.	2.2	14
48	Multiplexed Detection of Antibodies Using Programmable Bead Arrays. Methods in Molecular Biology, 2011, 723, 227-238.	0.9	13
49	Construction and Analysis of the NCI-EDRN Breast Cancer Reference Set for Circulating Markers of Disease. Cancer Epidemiology Biomarkers and Prevention, 2015, 24, 435-441.	2.5	13
50	Lost in the crowd: identifying targetable MHC class I neoepitopes for cancer immunotherapy. Expert Review of Proteomics, 2018, 15, 1065-1077.	3.0	12
51	T-Cell Epitope Discovery for Therapeutic Cancer Vaccines. Methods in Molecular Biology, 2016, 1403, 779-796.	0.9	11
52	Screening for HPV-related oropharyngeal, anal, and penile cancers in middle-aged men: Initial report from the HOUSTON clinical trial. Oral Oncology, 2021, 120, 105397.	1.5	11
53	Beyond Sequencing: Prioritizing and Delivering Neoantigens for Cancer Vaccines. Methods in Molecular Biology, 2022, 2410, 649-670.	0.9	11
54	Impaired tumor antigen processing by immunoproteasome-expressing CD40-activated B cells and dendritic cells. Cancer Immunology, Immunotherapy, 2011, 60, 857-867.	4.2	10

#	Article	IF	Citations
55	Pre-diagnostic dynamic HPV16 IgG seropositivity and risk of oropharyngeal cancer. Oral Oncology, 2017, 73, 132-137.	1.5	10
56	The feasibility of using an autologous GM-CSF-secreting breast cancer vaccine to induce immunity in patients with stage IIâ€“III and metastatic breast cancers. Breast Cancer Research and Treatment, 2022, 194, 65-78.	2.5	10
57	Solvent selective membrane routing and microfluidic architecture towards centrifugal automation of customisable bead based immunoassays. Sensors and Actuators B: Chemical, 2022, 356, 131305.	7.8	8
58	Crucial considerations for pipelines to validate circulating biomarkers for breast cancer. Expert Review of Proteomics, 2016, 13, 201-211.	3.0	6
59	An Automated Microfluidic Assay for Photonic Crystal Enhanced Detection and Analysis of an Antiviral Antibody Cancer Biomarker in Serum. IEEE Sensors Journal, 2018, 18, 1464-1473.	4.7	5
60	HPV: Immunology lessons from an ancient oncotarget. Oncotarget, 2019, 10, 1269-1270.	1.8	4
61	Is 2045 the best we can do? Mitigating the HPV-related oropharyngeal cancer epidemic. Expert Review of Anticancer Therapy, 2022, 22, 751-761.	2.4	4
62	Proteomic Monitoring of B Cell Immunity. Methods in Molecular Biology, 2016, 1403, 131-152.	0.9	3
63	Unique genomic and neoepitope landscapes across tumors: a study across time, tissues, and space within a single lynch syndrome patient. Scientific Reports, 2020, 10, 12190.	3.3	3
64	Weakly immunogenic CRISPR therapies. Nature Biomedical Engineering, 2019, 3, 761-762.	22.5	2
65	Autoantibodies and Biomarker Discovery. , 2013, , 363-378.		1
66	Pre-diagnostic dynamic HPV16 IgG seropositivity and risk of oropharyngeal cancer: Methodologic issues. Oral Oncology, 2018, 80, 93.	1.5	1
67	Safety and feasibility of intrathecal pembrolizumab infusion in refractory triple negative breast cancer with leptomeningeal disease: A case report. Current Problems in Cancer Case Reports, 2021, 4, 100103.	0.1	0